Pharmacokinetic studies for the estimation of bioequivalence of two DPIs containing budesonide and formoterol Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Safety of formoterol in asthma clinical trials Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Transition to extra-fine formulation of inhaled beclomethasone/formoterol improves clinical and functional parameters in controlled and partly controlled asthmatics Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Pooled analysis of the efficacy and safety from two non-interventional studies of fluticasone propionate/formoterol pMDI Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016
Pharmacokinetic and pharmacodynamic characteristics of HFA and CFC pMDI formulations of budesonide Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
A post-marketing study to evaluate the safety and tolerability of a non-chlorofluorocarbon salbutamol inhaler in asthmatic patients in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 78s Year: 2002
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Population pharmacokinetics of nebulized arformoterol in subjects with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID Year: 2021
Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Comparison of the efficacy and safety of budesonide administered via Clickhaler® or Turbuhaler® Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Confirmed clinical safety and efficacy of grass allergen tablets Source: Eur Respir J 2005; 26: Suppl. 49, 134s Year: 2005
Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Randomized double blind comparison of ciclesonide-formoterol combination inhaler and ciclesonide alone in persistent asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Pharmacokinetic bioequivalence of inhaled CHF 1535 50/6 vs. the free combination of beclomethasone and formoterol in asthmatic children Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007